• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Generation Bio Co.

    1/3/25 4:06:05 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GBIO alert in real time by email
    S-8 1 tmb-20250103xs8.htm S-8

    As filed with the Securities and Exchange Commission on January 3, 2025

    Registration No. 333-            

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    ​

    ​

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

    ​

    ​

    Generation Bio Co.

    (Exact Name of Registrant as Specified in Its Charter)

    ​

    ​

    Delaware

    ​

    81-4301284

    (State or Other Jurisdiction of

    Incorporation or Organization)

    ​

    (I.R.S. Employer

    Identification No.)

    ​

    301 Binney Street

    Cambridge, Massachusetts

    ​

    02142

    (Address of Principal Executive Offices)

    ​

    (Zip Code)

    ​

    2020 Stock Incentive Plan

    2020 Employee Stock Purchase Plan

    (Full Title of the Plan)

    ​

    Geoff McDonough, M.D.

    President and Chief Executive Officer

    301 Binney Street

    Cambridge, MA 02142

    (Name and Address of Agent for Service)

    ​

    (617) 655-6500

    (Telephone Number, Including Area Code, of Agent for Service)

    ​

    ​

    Copies to:

    ​

    Yalonda Howze

    Chief Legal Officer

    301 Binney Street

    Cambridge, MA 02142

    (617) 655-6500

    ​

    ​

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    ​

    ​

    ​

    ​

    ​

    ​

    Large accelerated filer

    ☐

    ​

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

    ​

    Smaller reporting company

    ☒

    ​

    ​

    ​

    Emerging growth company

    ☐

    ​

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

    ​

    ​

    ​


    PART I

    Statement of Incorporation by Reference

    This Registration Statement on Form S-8, relating to an aggregate of (a) 2,764,161 shares of common stock, $0.0001 par value per share (“Common Stock”), issuable under the 2020 Stock Incentive Plan of Generation Bio Co. (the “Registrant”), and (b) 669,804 shares of Common Stock issuable under the 2020 Employee Stock Purchase Plan of the Registrant, is being filed for the purpose of registering additional securities of the same class as other securities for which a Registration Statement on Form S-8 has previously been filed and is effective. Pursuant to General Instruction E to Form S-8, except as otherwise set forth below, this Registration Statement incorporates by reference the contents of:

    ●the Registration Statement on Form S-8, File No. 333-239116, relating to the 2017 Stock Incentive Plan, as amended, of the Registrant, the 2020 Stock Incentive Plan of the Registrant and the 2020 Employee Stock Purchase Plan of the Registrant, filed by the Registrant with the Securities and Exchange Commission on June 12, 2020,
    ●the Registration Statement on Form S-8, File No. 333-254429, relating to the 2020 Stock Incentive Plan of the Registrant and the 2020 Employee Stock Purchase Plan of the Registrant, filed by the Registrant with the Securities and Exchange Commission on March 18, 2021,  
    ●the Registration Statement on Form S-8, File No. 333-262980, relating to the 2020 Stock Incentive Plan of the Registrant and the 2020 Employee Stock Purchase Plan of the Registrant, filed by the Registrant with the Securities and Exchange Commission on February 24, 2022,
    ●the Registration Statement on Form S-8, File No. 333-269203, relating to the 2020 Stock Incentive Plan of the Registrant and the 2020 Employee Stock Purchase Plan of the Registrant, filed by the Registrant with the Securities and Exchange Commission on January 12, 2023, and
    ●the Registration Statement on Form S-8, File No. 333-277704, relating to the 2020 Stock Incentive Plan of the Registrant and the 2020 Employee Stock Purchase Plan of the Registrant, filed by the Registrant with the Securities and Exchange Commission on March 6, 2024.

    ​

    The information required by Part II is omitted, except as supplemented by the information set forth below.

    ​

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 8. Exhibits.

    The following exhibits are incorporated herein by reference:

     

    ​

    ​

    ​

    ​

    ​

    Number

        

    Description

    ​

    ​

    4.1

     

    Restated Certificate of Incorporation of the Registrant, as amended (incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q, File No. 001-39319, filed August 2, 2023).

    ​

    ​

    4.2

     

    Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, File No. 001-39319, filed April 4, 2023).

    ​

    ​

    5.1*

     

    Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Registrant

    ​

    ​

    23.1*

     

    Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1)

    ​

    ​

    23.2*

     

    Consent of Ernst & Young LLP, independent registered public accounting firm

    ​

    ​

    24.1*

     

    Power of attorney (included on the signature pages of this registration statement)

    ​

    ​

    99.1

     

    2020 Stock Incentive Plan (incorporated by reference to Exhibit 10.4 to the Registrant’s Registration Statement on Form S-1, File No. 333-238608, filed May 22, 2020).

    ​

    ​

    99.2

     

    2020 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.8 to the Registrant’s Registration Statement on Form S-1, File No. 333-238608, filed May 22, 2020).

    ​

    ​

    ​

    107*

    ​

    Calculation of Filing Fee Table


    ​

    *Filed herewith

    ​

    ​


    ​

    ​


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Cambridge, Massachusetts, on this 3rd day of January, 2025.

    ​

    ​

    ​

    ​

    ​

    Generation Bio Co.

    ​

    ​

    ​

    By:

    /s/ Geoff McDonough, M.D.

    ​

    ​

    Geoff McDonough, M.D.

    ​

    ​

    President and Chief Executive Officer

    ​

    ​

    ​

    ​

    ​

    ​


    POWER OF ATTORNEY AND SIGNATURES

    We, the undersigned officers and directors of Generation Bio Co., hereby severally constitute and appoint Geoff McDonough, M.D., Matthew Norkunas, M.D., MBA, Kevin Conway, Yalonda Howze, J.D., and Shawna-Gay White, J.D. and each of them singly (with full power to each of them to act alone), our true and lawful attorneys with full power of substitution and resubstitution in each of them for him or her and in his or her name, place and stead, and in any and all capacities, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Generation Bio Co. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

    ​

    ​

    ​

    ​

    ​

    ​

    Signature

        

    Title

        

    Date

    ​

    ​

    ​

    ​

    ​

    /s/ Geoff McDonough

    ​

    President, Chief Executive Officer and Director

    ​

    January 3, 2025

    Geoff McDonough, M.D.

    ​

    (principal executive officer)

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Matthew Norkunas

    ​

    Chief Financial Officer

    ​

    January 3, 2025

    Matthew Norkunas, M.D., MBA

    ​

    (principal financial officer)

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Dannielle Appelhans

    ​

    Director

    ​

    January 3, 2025

    Dannielle Appelhans

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Gustav Christensen

    ​

    Director

    ​

    January 3, 2025

    Gustav Christensen

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Ron Cooper

    ​

    Director

    ​

    January 3, 2025

    Ron Cooper

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Jeffrey Jonas

    ​

    Director

    ​

    January 3, 2025

    Jeffrey Jonas, M.D.

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Donald Nicholson

    ​

    Director

    ​

    January 3, 2025

    Donald Nicholson, Ph.D.

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Anthony Quinn

    ​

    Director

    ​

    January 3, 2025

    Anthony Quinn, M.B. Ch.B., Ph.D.

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Jason Rhodes

    ​

    Director

    ​

    January 3, 2025

    Jason Rhodes

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Charles Rowland

    ​

    Director

    ​

    January 3, 2025

    Charles Rowland

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Catherine Stehman-Breen

    ​

    Director

    ​

    January 3, 2025

    Catherine Stehman-Breen, M.D.

    ​

    ​

    ​

    ​

    ​


    Get the next $GBIO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GBIO

    DatePrice TargetRatingAnalyst
    12/16/2025$5.50Neutral → Outperform
    Wedbush
    12/16/2025$5.00Buy → Hold
    Jefferies
    8/13/2025$7.00Outperform → Neutral
    Wedbush
    10/19/2023Outperform → Market Perform
    TD Cowen
    11/8/2022$9.00Buy
    Canaccord Genuity
    12/15/2021$40.00 → $10.00Market Outperform
    JMP Securities
    12/15/2021$50.00 → $27.00Buy
    Needham
    12/14/2021Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $GBIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NodThera Appoints Geoff McDonough, M.D., as Chief Executive Officer

    Dr. McDonough brings global company-building, commercial strategy, and R&D leadership experience to the Company ahead of key clinical milestones NodThera plans to report results from two Phase 2 cardiometabolic trials RESOLVE-1 and RESOLVE-2 in mid-2026 and third quarter 2026 respectively Company preparing to begin cardiometabolic Phase 3 trial in 1H 2027 BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- NodThera, the leading clinical-stage NLRP3 company developing a portfolio of best-in-class brain-penetrant and immune-targeted oral inhibitors to address unmet needs in cardiometabolic and neuroinflammatory diseases driven by the NLRP3/IL-6/IL-1 inflammation pathway, announced the appointment o

    2/4/26 8:00:00 AM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs

    Experienced industry leader brings extensive expertise in leading breakthrough therapies through clinical development to marketing approval Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced the appointment of Antoinette Paone as Chief Development Officer ("CDO") and Head of Regulatory Affairs. Ms. Paone brings extensive experience leading regulatory strategy from clinical development through approval, including her work on Kalydeco and Orkambi at Vertex Pharmaceuticals (NASDAQ:VRTX). She joins Satellos from Generation Bio (NASDAQ:G

    1/29/26 7:00:00 AM ET
    $GBIO
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NodThera Appoints Geoff McDonough, M.D., as Independent Board Member

    BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- NodThera, a clinical-stage biotechnology company pioneering a paradigm shift in the treatment of chronic inflammatory diseases through selective NLRP3 inhibition, today announced the appointment of Geoff McDonough, M.D., as an Independent Board Member. Dr. McDonough brings more than two decades of leadership experience spanning R&D, commercial strategy, and global company building. He most recently served as President and Chief Executive Officer of Generation Bio (NASDAQ:GBIO). Dr. McDonough previously served as President and CEO of Sobi, overseeing substantial portfolio expansion and international growth. Earlier in his career, Dr. McDonough spen

    12/16/25 8:00:00 AM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GBIO
    SEC Filings

    View All

    Amendment: SEC Form SC TO-T/A filed by Generation Bio Co.

    SC TO-T/A - Generation Bio Co. (0001733294) (Subject)

    1/30/26 5:14:05 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 14D9/A filed by Generation Bio Co.

    SC 14D9/A - Generation Bio Co. (0001733294) (Subject)

    1/30/26 5:10:30 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC TO-T/A filed by Generation Bio Co.

    SC TO-T/A - Generation Bio Co. (0001733294) (Subject)

    1/12/26 7:58:22 AM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Conway Kevin John converted options into 235 shares and covered exercise/tax liability with 72 shares, increasing direct ownership by 9% to 2,072 units (SEC Form 4)

    4 - Generation Bio Co. (0001733294) (Issuer)

    2/4/26 4:05:30 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mcdonough Geoff covered exercise/tax liability with 550 shares and converted options into 1,582 shares, increasing direct ownership by 0.75% to 138,492 units (SEC Form 4)

    4 - Generation Bio Co. (0001733294) (Issuer)

    2/4/26 4:05:27 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    INTERIM CEO & PRESIDENT Howze Yalonda converted options into 1,673 shares and covered exercise/tax liability with 495 shares, increasing direct ownership by 46% to 3,759 units (SEC Form 4)

    4 - Generation Bio Co. (0001733294) (Issuer)

    2/4/26 4:05:25 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Quinn Anthony G. bought $203,209 worth of shares (210,791 units at $0.96), increasing direct ownership by 238% to 299,286 units (SEC Form 4)

    4 - Generation Bio Co. (0001733294) (Issuer)

    1/14/25 4:05:17 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Appelhans Dannielle bought $14,339 worth of shares (8,000 units at $1.79), increasing direct ownership by 5% to 12,637 units (SEC Form 4)

    4 - Generation Bio Co. (0001733294) (Issuer)

    12/11/23 4:30:19 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Appelhans Dannielle bought $18,000 worth of shares (12,000 units at $1.50) (SEC Form 4)

    4 - Generation Bio Co. (0001733294) (Issuer)

    12/6/23 4:30:13 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Generation Bio upgraded by Wedbush with a new price target

    Wedbush upgraded Generation Bio from Neutral to Outperform and set a new price target of $5.50

    12/16/25 12:29:16 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Generation Bio downgraded by Jefferies with a new price target

    Jefferies downgraded Generation Bio from Buy to Hold and set a new price target of $5.00

    12/16/25 8:41:52 AM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Generation Bio downgraded by Wedbush with a new price target

    Wedbush downgraded Generation Bio from Outperform to Neutral and set a new price target of $7.00

    8/13/25 8:02:22 AM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Generation Bio Co.

    SC 13G/A - Generation Bio Co. (0001733294) (Subject)

    12/9/24 6:18:02 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Generation Bio Co.

    SC 13G/A - Generation Bio Co. (0001733294) (Subject)

    11/14/24 1:22:38 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Generation Bio Co. (Amendment)

    SC 13G/A - Generation Bio Co. (0001733294) (Subject)

    2/14/24 10:03:03 AM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GBIO
    Financials

    Live finance-specific insights

    View All

    XOMA Royalty Enters into Agreement to Acquire Generation Bio

    - Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio's collaboration with Moderna - - Generation Bio's cell-targeted lipid nanoparticles (ctLNP) delivery platform for small interfering RNA (siRNA) and other nucleic acid therapies to be included in XOMA Royalty's portfolio - EMERYVILLE, Calif. and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA), the biotech royalty aggregator, announced today it has entered into an agreement to acquire Generation Bio Co. ("Generation Bio") (NASDAQ:GBIO) for a cash price of $4.2913 per share at the closing of the merger. Generation Bio stockholders

    12/15/25 5:00:00 PM ET
    $GBIO
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GBIO
    Leadership Updates

    Live Leadership Updates

    View All

    NodThera Appoints Geoff McDonough, M.D., as Chief Executive Officer

    Dr. McDonough brings global company-building, commercial strategy, and R&D leadership experience to the Company ahead of key clinical milestones NodThera plans to report results from two Phase 2 cardiometabolic trials RESOLVE-1 and RESOLVE-2 in mid-2026 and third quarter 2026 respectively Company preparing to begin cardiometabolic Phase 3 trial in 1H 2027 BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- NodThera, the leading clinical-stage NLRP3 company developing a portfolio of best-in-class brain-penetrant and immune-targeted oral inhibitors to address unmet needs in cardiometabolic and neuroinflammatory diseases driven by the NLRP3/IL-6/IL-1 inflammation pathway, announced the appointment o

    2/4/26 8:00:00 AM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs

    Experienced industry leader brings extensive expertise in leading breakthrough therapies through clinical development to marketing approval Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced the appointment of Antoinette Paone as Chief Development Officer ("CDO") and Head of Regulatory Affairs. Ms. Paone brings extensive experience leading regulatory strategy from clinical development through approval, including her work on Kalydeco and Orkambi at Vertex Pharmaceuticals (NASDAQ:VRTX). She joins Satellos from Generation Bio (NASDAQ:G

    1/29/26 7:00:00 AM ET
    $GBIO
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NodThera Appoints Geoff McDonough, M.D., as Independent Board Member

    BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- NodThera, a clinical-stage biotechnology company pioneering a paradigm shift in the treatment of chronic inflammatory diseases through selective NLRP3 inhibition, today announced the appointment of Geoff McDonough, M.D., as an Independent Board Member. Dr. McDonough brings more than two decades of leadership experience spanning R&D, commercial strategy, and global company building. He most recently served as President and Chief Executive Officer of Generation Bio (NASDAQ:GBIO). Dr. McDonough previously served as President and CEO of Sobi, overseeing substantial portfolio expansion and international growth. Earlier in his career, Dr. McDonough spen

    12/16/25 8:00:00 AM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care